$12.850
-0.407 (-3.17%)終値時点
KLRA の同業比較
In the context of the broader market, KLRA competes directly with industry leaders such as KRSA and CMPS. With a market capitalization of $1.67B, it holds a leading position in the sector. When comparing efficiency, KLRA's gross margin of N/A stands against KRSA's N/A and CMPS's N/A. Such benchmarking helps identify whether Kailera Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Kailera Therapeutics Inc の財務パフォーマンス
Kailera has shown a significant increase in current assets, rising from 530,315,000 USD in Q1 2026 to 929,167,000 USD in Q2 2026, indicating improved liquidity. However, the company is still facing large net losses, with EPS reported at -1.09 for Q2 2026.
Financials
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。